Histoire
juillet 1, 2026
Trump Reportedly Approves Plan to Fire FDA Commissioner Marty Makary
President Trump has reportedly approved a plan to fire Food and Drug Administration Commissioner Marty Makary amid conflicts over the agency's agenda. When questioned, Trump stated he was unaware of such plans, and a White House spokesperson said a final decision had not been made.
President Trump’s reported approval of a plan to fire FDA Commissioner Marty Makary has exposed a striking disconnect between internal deliberations and the administration’s public denials, raising broader questions about who is actually steering federal health policy.
Liberal-leaning reporting emphasizes the substance of the personnel move and its policy stakes. CBS News reports that Trump “has approved a plan to fire Food and Drug Administration Commissioner Marty Makary, according to two sources,” noting that the Wall Street Journal first revealed the president had “signed off” on Makary’s ouster after clashes over the FDA’s agenda, especially flavored e‑cigarettes.1 Makary reportedly resisted approving fruit‑flavored vapes until Trump personally pressured him, with advisers portraying Makary as “blocking the vaping agenda” and a “problem for the Trump administration.”1
Coverage from The Gateway Pundit, while equally centered on the firing plan, casts it as part of wider turmoil inside the health bureaucracy. Citing major outlets, it recounts “a tumultuous period for the regulator that included clashes over vaping, abortion and drug policy,” and describes Makary as “struggling to manage his agency” and “sparring frequently with health department officials and at times with the White House.”2 It situates Makary as merely the latest official pushed out under HHS Secretary Robert F. Kennedy Jr., following top CDC and HHS departures.2
Where the accounts converge is on Trump’s attempt to distance himself in public. Asked directly if he was going to fire Makary, Trump replied, “I’ve been reading about it. I know nothing about it,” even as unnamed officials insisted he had already signed off on a removal plan.2 A White House spokesperson adds further ambiguity, saying Trump “hasn’t completely made up his mind,” while touting “the most experienced and talented administration in history.”2
Taken together, these narratives contrast an assertive, behind‑the‑scenes president shaping FDA policy with a publicly evasive one, and pit a commissioner portrayed alternately as a policy roadblock or managerial failure against an administration whose own message cannot quite explain why he is on the chopping block.